Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiaries received approval from the State Drug Administration to issue “Recent Drug Clinical Trial Approval Notice” for HRS-7172 tablets, adbelizumab injections, SHR-4610 injections, SHR-8068 injections, SHR-9839 (sc) for injections, bevacizumab SHR injections, HRS-4642 injections, HRS-6093 tablets, and HRS-7058 capsules, which will be launched clinical trials.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.